Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBI-902
- Development stage
- Phase 2
- Lead developer
- OBI Pharma
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OBI-902 is a novel antibody-drug conjugate (ADC) developed by OBI Pharma using its proprietary GlycOBI platform, a glycan-based site-specific conjugation technology designed to improve stability and hydrophilicity. The drug specifically targets Trop-2, a cell surface antigen highly expressed in various solid tumors such as breast, ovarian, gastric, pancreatic, colorectal, and non–small cell lung cancers. OBI-902 carries a potent topoisomerase I inhibitor payload with a drug-antibody ratio (DAR) of 4. Preclinical studies have demonstrated that OBI-902 exhibits enhanced linker-payload stability, favorable pharmacokinetics, and superior antitumor activity compared to benchmark Trop-2 ADCs. The agent is currently being evaluated in phase 1/2 clinical trials for advanced solid tumors[1][2][5][9].
- Other names
- OBI-902 TROP2 ADCOBI902 TROP2 ADCOBI 902 TROP2 ADC
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on OBI-902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBI-902.